Major Advances in Diagnosing Cancers Associated With the Human Papillomavirus
The Institut de Cancérologie de Lorraine [the Lorraine Institute of Oncology, or ICL] in collaboration with the Institut du Cancer Joliot Curie [the Joliot Curie Cancer Institute] in Dakar and the Cerba HealthCare Group has recently finalized research demonstrating that it is possible to diagnose certain cancers caused by the human papillomavirus (HPV) through a simple blood test.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211124006043/en/
Based on the innovative CaptHPV technique, this research recently published in the journal ClinicalCancer Research* raises the prospect of a non-invasive approach to diagnosing certain cancers and optimizing biological monitoring of patients receiving therapy.
A ten-year scientific endeavour combining the expertise of public and private players
Studies conducted in the last twenty years have shown that small fragments of DNA from tumour cells are present in the blood of people with cancer. However, these fragments are difficult to locate since they are mixed in with large amounts of “normal” DNA.
Faced with the difficulty of distinguishing between tumour DNA and non-tumour DNA, ICL teams concentrated their efforts on types of cancers caused by viruses, specifically human papillomaviruses (HPV). They decided to test the hypothesis that it was possible to diagnose cancers associated with these viruses, regardless of the type of cancer or type of virus, in a different way. The ICL teams drew upon an innovative technique called CaptHPV, initially created to analyse tumours. For this new study, the technique was adapted to be used in analysing blood samples. This method makes it possible to detect all types of HPV identified to date and to obtain their full characteristics using what is called next- generation sequencing or NGS.
In 2016, the CaptHPV clinical trial was set up by the ICL in collaboration with a medical team from Senegal (a country with a different prevalence of certain types of HPV than France) and Cerba HealthCare, an expert in tumour biomarker analysis.
Promising results for diagnosing and monitoring patients
At the end of the study, the results obtained in each laboratory were compared. That comparison showed strong consistency between the two types of samples. More specifically, for 77 out of 80 patients with an HPV-associated cancer, the blood sample analysis yielded the same results as the tumour analysis, which is a sensitivity of 95%.
In just one of 54 cases of HPV-negative cancer, the blood test found fragments of viral DNA (a specificity of 98.1%). Furthermore, based on the blood sample, the original method provided a detailed description of the nature and characteristics of the viral genome associated with the tumour.
In certain situations, diagnosing HPV-associated cancer can be difficult using traditional approaches that rely on collecting a tumour tissue sample. This is particularly true for cases of suspected recurrence in a patient originally treated for a given type of tumour who now presents with minimal symptoms and deep lesions that are difficult to distinguish on X-Rays or difficult to access. In these cases, but for all patients broadly speaking, blood sample analysis is a simple, non-invasive alternative to imaging-guided biopsies which can never be entirely risk free.
“Detecting viral DNA circulating in the blood would be an important biological component for optimising biological monitoring of patients during treatment as well as post-therapeutic observation. The fact that the viral profile of the tumour has previously been precisely defined will make it possible to know the main parameters on which the follow-up lab work will be based,” explains Prof. Alexandre Harlé – a university lecturer and hospital practitioner at the ICL/University of Lorraine and the clinical pathologist responsible for the study coordination.
“In the longer term, it is very likely that new treatments -such as immunotherapy or therapeutic vaccine therapy- based on stimulating the immune system and aimed at viral sequences will require accurate prior knowledge of the characteristics of the viral sequences being targeted by these personalised treatments. Here again, being able to define the viral profile, regardless of the type of virus, based on a blood sample that can easily be repeated over time is a very interesting outlook,” states Dr Xavier Sastre-Garau, a pathologist and principal investigator of the study.
Jérôme Sallette, Chief Scientific Officer of Cerba HealthCare, adds: “Liquid biopsies, and non-invasive diagnostic methods more generally, are a major area of research for cancer diagnosis thanks to the power of the next-generation sequencing that the Cerba HealthCare Group has successfully and routinely conducted since 2013. The opportunity offered by our skills in this area and the presence of our Group in Africa have been major advantages for our contribution to the work being done by the ICL. This work once again demonstrates the immense added value of public-private collaborations to advance research and to be able to offer patients and clinicians less invasive tools for earlier diagnoses. They lead to interesting possibilities for combat certain cancers in addition to screening, the importance of which cannot be stressed enough.”
On a more fundamental level, this new approach will undoubtedly improve our knowledge of the biological mechanisms that influence tumour development.
In the long term, the work being conducted specifically on tumours associated with human papillomavirus should pave the way to optimizing diagnosis and monitoring of tumours associated with other viruses. Finally, the sensitivity and specificity observed in this study lay the groundwork for designing similar approaches for other types of tumours characterised by specific genetic alterations.
*Open access article (in English):
https://clincancerres.aacrjournals.org/content/early/2021/06/08/1078-0432.CCR-21-0293.long
Additional information available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124006043/en/
Contact information
ICL Press
Alexandra Cravotta
03 83 59 86 05 / 06 86 40 81 50
a.cravotta@nancy.unicancer.fr
Cerba HealthCare Press
Aurélie Le Franc
07 50 12 18 34
aurelie.lefranc@cerbahealthcare.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Saudi Arabia Highlights Investment Initiatives in Tourism at International Hospitality Investment Forum 17.4.2024 19:51:00 CEST | Press release
The Saudi Ministry of Tourism is currently taking a prominent stage at the International Hospitality Investment Forum (IHIF), presenting a unique opportunity for global investors to dive into the thriving tourism landscape of the Kingdom. With the spotlight on the Tourism Investment Enablers Program (TIEP), that was recently announced, Saudi Arabia is aggressively pushing towards its Vision 2030 goal of being a top global tourism destination for investors and tourists alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417879947/en/ Mr. Mahmoud Abdullhadi, Deputy Minister of Destinations Enablement. (Photo: AETOSWire) This strategic presentation comes at a time when Saudi Arabia's tourism sector celebrates an incredible milestone of 100 million visitors in 2023, seven years ahead of schedule, marking a significant stride towards economic diversification and emphasizing the sector's growing contribution to the nationa
Kai Tak Sports Park Limited and ASM Global Begin Countdown to Unveiling of World’s Largest Sports Development in History17.4.2024 15:00:00 CEST | Press release
The Hong Kong Special Administrative Region Government, ASM Global and Kai Tak Sports Park Limited (KTSPL) — which is a subsidiary of New World Development — as part of a multiyear strategy, have announced a late winter testing period for Kai Tak marking the culmination of a near decade-long record $4 billion project creating the premiere sports, recreation, entertainment complex on Earth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417546819/en/ PLAY BALL – Kai Tak Sports Park, the largest and most ambitious sports-development and entertainment district in the world, is being managed by ASM Global. (Photo: Business Wire) ASM Global, as the lead operator, has been on the ground in Hong Kong working for over five years supporting the design, programming and construction of Kai Tak Sports Park, featuring many of the world’s most advanced state-of-the-art venues and is now prepping for pre-opening activities in advance of
Qualcomm Announces Quarterly Cash Dividend17.4.2024 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on June 20, 2024, to stockholders of record at the close of business on May 30, 2024. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority o
Games Global Announces Filing of Registration Statement for Proposed Initial Public Offering17.4.2024 14:17:00 CEST | Press release
Games Global Limited (“Games Global”), a leading developer, distributor and marketer of innovative online casino-style gaming content and integrated business-to-business solutions to iGaming operators globally based on the size of its studio network, announced today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. Games Global has applied to list its ordinary shares on the New York Stock Exchange under the symbol "GGL". J.P. Morgan, Jefferies and Macquarie Capital are acting as joint book-running managers for the proposed offering. Barclays is acting as bookrunner for the proposed offering. The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the propo
Alpega Group Recognized as a Challenger in the 2024 Gartner® Magic Quadrant™ for Transportation Management Systems17.4.2024 14:00:00 CEST | Press release
Alpega, a global leader in logistics SaaS software, announces its recognition as a Challenger in the 2024 Gartner Magic Quadrant for Transportation Management Systems (TMS). We believe this acknowledgment underscores Alpega’s unwavering commitment to delivering cutting-edge solutions tailored to meet the evolving demands of the transportation industry. The Gartner report evaluates vendors based on their completeness of vision and ability to execute. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417652913/en/ (Photo: Alpega) Alpega serves global customers with deployments in all geographies, addressing diverse sectors such as automotive, retail, fast-moving consumer goods, and manufacturing, Alpega places significant emphasis on fostering collaboration with carriers, optimizing transportation procurement, and championing environmental, social, and governance (ESG) initiatives. Backed by a history of exceptional customer r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom